Naturally Occurring Benzodiazepines, Endozepines, and their Receptors
Implications for Benzodiazepine Therapy and Withdrawal
- Available for pre-order. Item will ship after August 17, 2021
Understanding and addressing the current opioid crisis requires knowledge of the endogenous opioids (endorphins and enkephalins), but there is now evidence for a benzodiazepine crisis. Are there endogenous benzodiazepine-like substances – and what do they do? How do they affect the anti-anxiety drugs and their adverse effects? Do they explain the enigmatic prolonged benzodiazepine withdrawal syndrome? Naturally Occurring Benzodiazepines, Endozepines, and their Receptors: Implications for Benzodiazepine Therapy and Withdrawal raises important questions about the clinical consequences of ignoring the existence of or understanding the potential influence of endogenous benzodiazepines on the therapeutic effect of benzodiazepines, their adverse effects, and the problems of withdrawal from them and other benzodiazepine receptor agonists.
- Discusses endogenous benzodiazepine-like substances – what do they do, do they affect the anti-anxiety drugs and their adverse effects?
- Presents information on the enigmatic prolonged benzodiazepine withdrawal syndrome
- Describes the compounds acting at the BDZ binding sites, both exogenous (classical BDZ drugs and BDZ from food and plants) and endogenous (endozepines)
- Assesses the putative interactions in physiology, pathology and pharmacology of the compounds acting at the BDZ binding sites
Table of Contents
Preface RB Raffa & D Amantea
Section I: Introduction and Basic Principles
Chapter 1 Introduction
Chapter 2 Benzodiazepines and Related Substances: Chemistry
F Grande, MA Occhiuzzi & A Garofalo
Chapter 3 Central Benzodiazepine Receptors: Structure and Function
Chapter 4 Benzodiazepines and Related Substances: Therapeutic Uses and Problems
Chapter 5 Peripheral Benzodiazepine Receptors
Section II: Naturally-occurring Benzodiazepines
Chapter 6 The search for Endogenous Benzodiazepines in Humans
Chapter 7 Evidence for Presence in Non-human Animals
Oné Pagan, PhD
Chapter 8 Biologically Active Phytochemicals Having Benzodiazepine-like Actions
D Montesano & M Gallo
Chapter 9 Benzodiazepines, Flavonoids and GABA
T Hinton & G Johnston
Chapter 10 The Microbiome and Benzodiazepines: A Connection?
Section III: Implications for Therapeutics
Chapter 11 Anxiety, Sleep, and Benzodiazepines
Chapter 12 The Effects of Benzodiazepines on Memory
Chapter 13 Naturally Occurring and Exogenous Benzodiazepines in Epilepsy: An Update
F-M Werner & R Coveñas
Section IV: Implications for Tolerance, Withdrawal, Abuse
Chapter 14 Impact of Endogenous Benzodiazepines on Tolerance, Abuse, or Withdrawal
RB Raffa & D Amantea
Dr. Raffa is Adjunct Professor at the University of Arizona College of Pharmacy and Professor Emeritus at Temple University School of Pharmacy. He earned bachelor’s degrees in Chemical Engineering and in Physiological Psychology (both from the University of Delaware), master’s degrees in Biomedical Engineering (from Drexel University) and Toxicology (Thomas Jefferson University), and a doctorate in Pharmacology (Temple University School of Medicine). He was a Research Fellow and a Team Co-Leader for drug discovery at Johnson & Johnson. He is a cofounder of CaRafe Drug Innovation and Enalare Therapeutics, and is CSO of Neumentum Inc. He is co-holder of several patents and has published more than 350 papers. He has co-authored or edited several books on pharmacology and thermodynamics, is a Co-Editor of two journals, is a past president of the Mid-Atlantic Pharmacology Society and is the recipient of research and teaching awards.
Dr. Amantea is Associate Professor of Pharmacology at the Department of Pharmacy, Health and Nutritional Sciences of the University of Calabria (Italy), where she is the leader of the Stroke Research Unit at the Section of Preclinical and Translational Pharmacology operating in the frame of the Italian Stroke Organization (ISO) Basic Science. She earned a PharmD cum laude from the University of Calabria in 1998 and a PhD in Pharmacology from the University of Birmingham (UK) in 2003. She continued her postdoctoral activity at the Department of Pharmacology of the Medical School of Birmingham University where, under the guidance of Prof. Norman G. Bowery, she worked on the involvement of GABAB receptors in neurological disorders. During her formative years, she was visiting researcher at respected research laboratories of the Universities of Madrid, Lausanne, Florence and Rome. She published more than 60 papers on peer-reviewed journals. She is member of the Editorial Board and Guest Editor of the 2016 Neuroscience section of Current Opinion in Pharmacology (Elsevier), Founder and editor of “Frontiers in Neurotherapeutics” series (CRC press).